Arrhythmias & electrophysiologyMeta-analysis
Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis
- Systematic review and meta-analysis of randomised trials
- random-effects
Study context
- Population
- Patients in randomized clinical trials (RCTs) of cardio-renal-metabolic medications (HF, CKD, obesity and other cardio-renal-metabolic diseases)
- Participants
- 745,041 patients · 249 RCTs
- Comparison
- Non-antiarrhythmic cardio-renal-metabolic medication vs control or another agent
- Outcome
- Incident AF
Pooled result
As reported in the abstract
Incident AF, placebo-controlled trials
Relative risk (95% CI)
ACEi and ARB vs PlaceboHFrEF
0.69(0.60–0.80)
MRA vs PlaceboHFrEF
0.62(0.43–0.90)
SGLT2 inhibitors vs PlaceboHFrEF
0.62(0.44–0.87)
SGLT2 inhibitors vs PlaceboCKD
0.53(0.33–0.85)
GLP-1 receptor agonists vs Placeboobesity
0.79(0.63–0.99)
Original publication
Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis. Eur Heart J. Published 28 January 2026. doi:10.1093/eurheartj/ehag021
Summarised from the published abstract; every number is checked against it